Opthea Limited, a biotechnology company focussed on retinal diseases, announced Sunday it is seeking an initial public offering in the United States.
What Happened: The Melbourne Australia-based biopharmaceutical company will offer American Depositary Shares each of which will represent eight of the company’s ordinary shares.
Opthea is targeting $160 million in gross proceeds in the offering and is giving underwriters a 30-day option to purchase an additional 15% of the ADSs in the IPO.
The ADSs will be listed on the Nasdaq Stock Market under the symbol “OPT.”
Citigroup Inc C and SVB Leerink have been appointed as joint book-running managers, while Oppenheimer Holdings Inc OPY-subsidiary Oppenheimer & Co and Truist Financial Corporation's TFC division Truist Securities are acting as lead managers.
On Monday, at press-time, the company’s shares traded at $2.18 in Sydney, which would price an ADR at $17.44.
Why It Matters: Opthea’s focus is on developing a novel therapy for highly preventable and progressive retinal diseases including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
The company’s lead clinical candidate OPT-302 is under development for use in combination with anti-VEGF-A monotherapies.
The company — founded in 2012 — raked in $1 million in revenue for 12 months ended June 30, according to Renaissance Capital.
Photo courtesy of Opthea
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
